Han Kun Advises Connect Biopharma on its U.S. IPO and Listing on the Nasdaq Global Market
Han Kun has advised Connect Biopharma Holdings Limited as its PRC legal advisor in connection with the company's U.S. initial public offering and listing on the Nasdaq Global Market under the symbol "CNTB."
Founded in 2012, Connect Biopharma is dedicated to clinical stage research and development of novel immunomodulators for the treatment of severe autoimmune diseases and inflammation. Connect Biopharma has built a high-throughput drug screening platform based on T cell immune regulation function, based on its T cell immune regulation technology platform and the strength of expertise and experience in the field of immunology. Compared with traditional methods, Connect Biopharma's platform is able to quickly and efficiently identify and screen molecules against target diseases.